Can you please ask the following questions to management for me.
1. Was there an independent valuation obtained for the acquisition of the remainder of MCL. Appears to be disproportionate in value relative to the initial 55%.
2. Was there an independent valuation for Medcan? Given all there is to this company is the ODC licence why is it worth 250 m in QBL shares when the original agreement with MCL was to grant AK an additional 50 m in performance shares on MCL obtaining the ODC licence. Seems to me that the Medcan ODC is now valued at 5 times more than what was offered to MCL.
3. Linked to 2, given that QBL bought the ODC licence, why should the 50 m in performance shares be issued?
Thanks in advance.
In relation to the 50 million performance shares.
QBL Price at posting:
5.7¢ Sentiment: Hold Disclosure: Held
